BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Advances NanoAb Therapy as IL-17 Drug Candidate for Psoriasis Treatment
Similar business model but different antibody therapies for psoriasis treatment, BiondVax uses NanoAbs while Apogee Therapeutics, Inc. uses conventional mAbs BiondVax NanoAbs provide superior benefits not seen in mAb therapies, including new routes of administration, higher affinity, better binding, and a higher level of stability at room temperature Apogee recently went public at $500 million pre-money, raising $300 million in an upsized deal, and has a $1 billion market cap – should be an eye-opener to BiondVax investors who recognize benefits of NanoAbs over mAb development The global psoriasis treatment market was valued at $26.13 billion in 2022 and is…











